Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Blood biomarker test improves detection of hidden brain injuries (opens in a new tab)

news-medical.net · 2026-10-23

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

3 claims go further than the study.

  • 1 supported
  • 3 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Three of four claims overstate the study. One of four checks out.

  • 1 supported
  • 3 overstated
Open claim evidence
3

The source study

Clinical cutoffs for plasma biomarkers to identify intracranial pathology in traumatic brain injury patients with Glasgow Coma Scale scores 13 to 15: a TRACK-TBI study

Journal of Neurosurgery · 2026
Open source record (opens in a new tab)
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    Clinical cutoffs for plasma biomarkers to identify intracranial pathology in traumatic brain injury patients with Glasgow Coma Scale scores 13 to 15: a TRACK-TBI study

    Journal of Neurosurgery · 2026

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Clinical cutoffs for plasma biomarkers to identify intracranial pathology in traumatic brain injury patients with Glasgow Coma Scale scores 13 to 15: a TRACK-TBI study

    Where the story links (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedA multi-institutional research team led by University of Pittsburgh clinician-scientists reported clinical cutoffs for two blood proteins that may help better identify and triage patients with traumatic brain injury.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a multicenter TRACK-TBI secondary analysis in mild TBI, with day-1 blood biomarkers GFAP and UCH-L1 evaluated for identifying intracranial pathology and possible triage use. However, the paper profile reports cross-validated clinical cutoff derivation for GFAP, while UCH-L1 is mainly compared and performs poorly; it does not support equal clinical cutoffs for both proteins at this depth. The University of Pittsburgh leadership detail is not verifiable from the supplied abstract-level profile.

1

Study evidence

Day-1 plasma GFAP discriminated CT+ versus CT− with good accuracy (AUC 0.82, 95% CI 0.80–0.84); UCH-L1 showed poor discrimination (AUC 0.60, 95% CI 0.57–0.63).AUC GFAP 0.82 (95% CI 0.80–0.84); AUC UCH-L1 0.60 (95% CI 0.57–0.63)

“This is a secondary analysis of prospectively collected data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, which is a longitudinal, observational study”
2

Study evidence

For discriminating CT+ versus CT− among TRACK-TBI participants with GCS 13–15, day-1 plasma GFAP had AUC 0.82 (95% CI 0.80–0.84) and UCH-L1 had AUC 0.60 (95% CI 0.57–0.63).GFAP AUC 0.82 (95% CI 0.80–0.84); UCH-L1 AUC 0.60 (95% CI 0.57–0.63)

“Receiver operating characteristic curve analysis (AUC) was performed to evaluate the ability of day-1 GFAP and UCH-L1 to discriminate CT+ versus CT−, and CT−/MRI+ versus CT−/MRI−.”
Claim 2 of 4OverstatedThe article says the test may help decide whether a CT scan is needed in mild TBI, and that a point-of-care whole-blood version can rule out unnecessary imaging in about 15 minutes.View evidenceHide evidence

As stated15 minutes

Why this verdict

The profile supports potential triage relevance for GFAP thresholds to identify CT-positive intracranial pathology and guide urgent neuroimaging. But the paper profile describes plasma GFAP cutoffs targeting high positive predictive value, not a point-of-care whole-blood test that rules out unnecessary CT imaging. The 15-minute point-of-care claim is not verifiable from the abstract-level profile, and the 'rule out' framing outruns the reported PPV/rule-in threshold evidence.

1

Study evidence

Day-1 plasma GFAP discriminated CT+ versus CT− with good accuracy (AUC 0.82, 95% CI 0.80–0.84); UCH-L1 showed poor discrimination (AUC 0.60, 95% CI 0.57–0.63).AUC GFAP 0.82 (95% CI 0.80–0.84); AUC UCH-L1 0.60 (95% CI 0.57–0.63)

“This is a secondary analysis of prospectively collected data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, which is a longitudinal, observational study”
Claim 3 of 4OverstatedThe story also says CT scans can miss intracranial pathology in about 25% of patients, and that some patients with negative CT scans have abnormalities on MRI that would warrant specialized follow-up care.View evidenceHide evidence

As statedapproximately 25%

Why this verdict

The profile supports that among CT-negative participants who underwent MRI at about 2 weeks, 154 of 608, or about 25%, were MRI-positive. The story overgeneralizes this as CT scans missing pathology in about 25% of patients, without preserving the denominator: CT-negative patients selected for follow-up MRI. The claim that MRI abnormalities would warrant specialized follow-up care is plausible in triage context but not directly established in the abstract-level profile as stated.

1

Study evidence

Day-1 plasma GFAP discriminated CT− patients who were MRI+ from those who were MRI− with moderate accuracy.AUC 0.76 (95% CI 0.71–0.81)

“Of the 1085 CT− participants, 608 underwent MRI at 2 weeks postinjury”
2

Study evidence

For discriminating CT+ versus CT− among TRACK-TBI participants with GCS 13–15, day-1 plasma GFAP had AUC 0.82 (95% CI 0.80–0.84) and UCH-L1 had AUC 0.60 (95% CI 0.57–0.63).GFAP AUC 0.82 (95% CI 0.80–0.84); UCH-L1 AUC 0.60 (95% CI 0.57–0.63)

“Receiver operating characteristic curve analysis (AUC) was performed to evaluate the ability of day-1 GFAP and UCH-L1 to discriminate CT+ versus CT−, and CT−/MRI+ versus CT−/MRI−.”
Claim 4 of 4SupportedThe study focused on glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase-L1 (UCH-L1), and the article says GFAP could differentiate patients with acute brain injury from those with no evidence of pathology on neuroimaging within 24 hours of TBI.View evidenceHide evidence

Why this verdict

The profile supports that the study evaluated GFAP and UCH-L1 in blood collected within 24 hours and found GFAP discriminated CT-positive from CT-negative acute intracranial pathology with AUC 0.82, while UCH-L1 performed much worse. The story’s hedged framing that GFAP could differentiate patients with acute brain injury from those without neuroimaging pathology is consistent with the abstract-level evidence.

1

Study evidence

Day-1 plasma GFAP discriminated CT+ versus CT− with good accuracy (AUC 0.82, 95% CI 0.80–0.84); UCH-L1 showed poor discrimination (AUC 0.60, 95% CI 0.57–0.63).AUC GFAP 0.82 (95% CI 0.80–0.84); AUC UCH-L1 0.60 (95% CI 0.57–0.63)

“This is a secondary analysis of prospectively collected data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, which is a longitudinal, observational study”
2

Study evidence

For discriminating CT+ versus CT− among TRACK-TBI participants with GCS 13–15, day-1 plasma GFAP had AUC 0.82 (95% CI 0.80–0.84) and UCH-L1 had AUC 0.60 (95% CI 0.57–0.63).GFAP AUC 0.82 (95% CI 0.80–0.84); UCH-L1 AUC 0.60 (95% CI 0.57–0.63)

“Receiver operating characteristic curve analysis (AUC) was performed to evaluate the ability of day-1 GFAP and UCH-L1 to discriminate CT+ versus CT−, and CT−/MRI+ versus CT−/MRI−.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The MRI-based findings have subset and timing limitations: MRI analyses included only 608 of 1085 CT-negative participants and MRI occurred about 2 weeks after injury.

    The story notes that MRI is more sensitive but impractical for emergency triage, but it does not mention the selection of CT-negative patients who underwent MRI or the approximately 2-week MRI timing, both of which affect interpretation of the 25% MRI-positive figure.

    From secondary analysis of multicenter prospective cohort (TRACK-TBI); secondary analysis of prospective observational cohort

3 things the story did carry across
  • The study was a secondary analysis of the multicenter prospective observational TRACK-TBI cohort, restricted to mild TBI participants with GCS 13–15 presenting within 24 hours.
  • GFAP showed stronger discrimination than UCH-L1 for CT-positive pathology: GFAP AUC 0.82 versus UCH-L1 AUC 0.60.
  • Among CT-negative patients who underwent MRI at about 2 weeks, GFAP moderately discriminated MRI-positive from MRI-negative cases, and 154/608, about 25%, were MRI-positive.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataDerive plasma GFAP (and compare UCH-L1) cutoffs that achieve specified high positive predictive values for detecting acute intracranial pathology on head CT in mild TBI (GCS 13–15) patients presenting within 24 hours.Secondary analysis of multicenter prospective observational cohortExpand

In plain English

Secondary analysis of TRACK-TBI prospective cohort data (n=1718 with GCS 13–15) evaluating day-1 plasma GFAP and UCH-L1 to identify acute intracranial pathology on head CT. ROC analysis and K-fold cross-validation were used to derive GFAP cutoffs that achieve prespecified high adjusted positive predictive values (PPVs) for CT+ detection under assumed prevalence scenarios.

Key findings

  • Day-1 plasma GFAP discriminated CT+ versus CT− with good accuracy (AUC 0.82, 95% CI 0.80–0.84); UCH-L1 showed poor discrimination (AUC 0.60, 95% CI 0.57–0.63).AUC GFAP 0.82 (95% CI 0.80–0.84); AUC UCH-L1 0.60 (95% CI 0.57–0.63)
  • Cross-validated GFAP thresholds estimated to achieve high adjusted PPVs for CT+ detection depend on assumed prevalence: median GFAP 2879 pg/mL (95% CI 2195–4704) for PPV=0.9 assuming prevalence 0.36; median 5191 pg/mL (95% CI 3779–5426) for PPV=0.9 assuming prevalence 0.1.GFAP cutoffs for PPV=0.9: 2879 pg/mL (2195–4704) at prevalence 0.36; 5191 pg/mL (3779–5426) at prevalence 0.1
“This is a secondary analysis of prospectively collected data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, which is a longitudinal, observational study”
What this piece can’t prove
  • Analysis described is a secondary analysis of TRACK-TBI; abstract does not detail assay methods, full modeling specifications, or external validation.
  • PPV-based threshold values depend on assumed prevalence values; their performance will vary with prevalence in other settings.
  • MRI-based findings derive from a subset (608/1085 CT−) who underwent MRI ~2 weeks postinjury; potential selection or timing-related biases may affect MRI-related estimates.
2secondary dataDerive plasma GFAP (and compare UCH-L1) cutoffs that achieve specified high positive predictive values for detecting intracranial pathology on MRI at ~2 weeks among patients with negative initial CT (CT−/MRI+ vs CT−/MRI−).secondary analysis of multicenter prospective cohort (TRACK-TBI)Expand

In plain English

In a secondary analysis of TRACK-TBI, day-1 plasma GFAP and UCH-L1 were evaluated for discriminating CT− patients who had MRI evidence of acute TBI-related intracranial pathology at ~2 weeks (CT−/MRI+ vs CT−/MRI−). Among 608 CT− participants who underwent MRI, GFAP showed moderate discrimination (AUC 0.76) and UCH-L1 showed poor discrimination (AUC 0.60). Using K-fold cross-validation and adjusted PPV targets, median day-1 GFAP thresholds to predict MRI+ in the CT− GCS 13–15 subgroup were reported as 1382 pg/mL (95% CI 1145–2424) to achieve an adjusted PPV of 0.90 and 2317 pg/mL (95% CI 1262–2551) to achieve an adjusted PPV of 0.98.

Key findings

  • Day-1 plasma GFAP discriminated CT− patients who were MRI+ from those who were MRI− with moderate accuracy.AUC 0.76 (95% CI 0.71–0.81)
  • Day-1 plasma UCH-L1 showed poor discrimination for MRI-detected pathology among CT− patients.AUC 0.60 (95% CI 0.55–0.65)
“Of the 1085 CT− participants, 608 underwent MRI at 2 weeks postinjury”
What this piece can’t prove
  • Analysis restricted to the subset of CT− participants who underwent MRI (608 of 1085 CT− participants); potential selection bias in who received MRI.
  • MRI timing at ~2 weeks postinjury may identify lesions with different temporal dynamics than acute imaging; day-1 biomarker levels were used to predict later MRI findings.
  • Abstract does not report details on assay methods, thresholds' sensitivity/specificity, or the prevalence assumptions used for PPV adjustment for the MRI analyses.

1 further detail could not be confirmed from the summary.

3secondary dataQuantify and compare overall discriminative performance (ROC/AUC) of day-1 GFAP and UCH-L1 for (a) CT+ vs CT− and (b) CT−/MRI+ vs CT−/MRI− in this cohort.secondary analysis of prospective observational cohortExpand

In plain English

Abstract-level appraisal of ROC/AUC discrimination of day-1 plasma GFAP and UCH-L1 for two classification tasks in TRACK-TBI mild TBI participants (GCS 13–15): (a) CT+ versus CT−, and (b) among CT− patients, MRI+ versus MRI−. GFAP showed substantially higher AUCs than UCH-L1 for both tasks per reported estimates.

Key findings

  • For discriminating CT+ versus CT− among TRACK-TBI participants with GCS 13–15, day-1 plasma GFAP had AUC 0.82 (95% CI 0.80–0.84) and UCH-L1 had AUC 0.60 (95% CI 0.57–0.63).GFAP AUC 0.82 (95% CI 0.80–0.84); UCH-L1 AUC 0.60 (95% CI 0.57–0.63)
  • For discriminating MRI+ versus MRI− among CT− TRACK-TBI participants, day-1 plasma GFAP had AUC 0.76 (95% CI 0.71–0.81) and UCH-L1 had AUC 0.60 (95% CI 0.55–0.65).GFAP AUC 0.76 (95% CI 0.71–0.81); UCH-L1 AUC 0.60 (95% CI 0.55–0.65)
“Receiver operating characteristic curve analysis (AUC) was performed to evaluate the ability of day-1 GFAP and UCH-L1 to discriminate CT+ versus CT−, and CT−/MRI+ versus CT−/MRI−.”
What this piece can’t prove
  • MRI discrimination results derive from a subset of CT− participants who underwent MRI, which could introduce selection bias and affect generalizability.
  • Abstract does not report calibration, decision-curve analysis, or statistical comparison tests between AUCs (e.g., Delong), limiting inference about significance of differences.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Clinical cutoffs for plasma biomarkers to identify intracranial pathology in traumatic brain injury patients with Glasgow Coma Scale scores 13 to 15: a TRACK-TBI study

Journal of Neurosurgery · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 40 candidate papers

Selected

Clinical cutoffs for plasma biomarkers to identify intracranial pathology in traumatic brain injury patients with Glasgow Coma Scale scores 13 to 15: a TRACK-TBI study

Journal of Neurosurgery · 2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.